Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University.
Department of Pharmacology, Meiji Pharmaceutical University.
Biol Pharm Bull. 2024;47(7):1368-1375. doi: 10.1248/bpb.b24-00297.
We previously reported that the sustained component of contraction induced by depolarizing stimulation by high K concentration in rat caudal arterial smooth muscle involves a Ca-induced Ca sensitization mechanism whereby Ca entry through voltage-gated Ca channels activates proline-rich tyrosine kinase 2 (Pyk2), leading to activation of RhoA/Rho-associated kinase (ROCK). In the present study, we investigated a potential role for Pyk2-mediated RhoA/ROCK activation in contraction mediated by elevation of cytosolic free Ca concentration ([Ca]) induced by a Ca ionophore, ionomycin, rather than by depolarizing stimulation. Ionomycin (60 µM) induced slow and sustained contraction of rat caudal arterial smooth muscle due to influx of Ca. Pre-treatment with a myosin light chain kinase (MLCK) inhibitor, ML-9 (30 µM), inhibited both the early phase (4 min) and the sustained phase (30 min) of ionomycin-induced contraction. On the other hand, a ROCK inhibitor, HA-1077 (3 µM), and Pyk2 inhibitors, sodium salicylate (10 mM) and PF-431396 (3 µM), suppressed only the sustained phase of ionomycin-induced contraction. A calmodulin (CaM) inhibitor, W-7 (150 µM), but not W-5 (150 µM), suppressed the early phase of contraction. Early or sustained increase of ionomycin-induced 20 kDa light chain of myosin (LC) phosphorylation was inhibited by each inhibitor in a manner similar to the attenuation of contraction. These results indicate that the early phase of ionomycin-induced contraction is mediated by MLCK activation by [Ca] elevation, whereas the sustained phase of ionomycin-induced contraction involves RhoA/ROCK activation and inhibition of myosin light chain phosphatase (MLCP) through CaM-independent Pyk2 activation by [Ca] elevation.
我们之前报道过,在大鼠尾动脉平滑肌中,高浓度 K 引起的去极化刺激引起的收缩的持续成分涉及一种 Ca 诱导的 Ca 敏化机制,其中通过电压门控 Ca 通道的 Ca 内流激活富含脯氨酸的酪氨酸激酶 2(Pyk2),导致 RhoA/Rho 相关激酶(ROCK)的激活。在本研究中,我们研究了 Pyk2 介导的 RhoA/ROCK 激活在由肌浆网游离 Ca 浓度升高引起的收缩中的潜在作用[Ca] 通过钙离子载体离子霉素诱导,而不是通过去极化刺激。离子霉素(60μM)诱导大鼠尾动脉平滑肌的缓慢和持续收缩,原因是 Ca 的内流。肌球蛋白轻链激酶(MLCK)抑制剂 ML-9(30μM)预处理抑制了离子霉素诱导的收缩的早期阶段(4 分钟)和持续阶段(30 分钟)。另一方面,ROCK 抑制剂 HA-1077(3μM)和 Pyk2 抑制剂水杨酸钠(10mM)和 PF-431396(3μM)仅抑制了离子霉素诱导的收缩的持续阶段。钙调蛋白(CaM)抑制剂 W-7(150μM)但不是 W-5(150μM)抑制收缩的早期阶段。每种抑制剂以类似于收缩衰减的方式抑制离子霉素诱导的 20kDa 肌球蛋白轻链(LC)磷酸化的早期或持续增加。这些结果表明,离子霉素诱导的收缩的早期阶段是由[Ca]升高引起的 MLCK 激活介导的,而离子霉素诱导的收缩的持续阶段涉及 RhoA/ROCK 激活和通过[Ca]升高引起的 CaM 独立 Pyk2 激活抑制肌球蛋白轻链磷酸酶(MLCP)。